OpenNashPodcasts

Business Of Biotech

Modernizing Clinical Trial Operations With Merck's Jennifer Sheller

22 Dec 2025 · 55m · Jennifer Sheller, Ben Comer · 23 quoted facts

▶ Play episodeOriginal source ↗

In brief

Jennifer Sheller of Merck argues that clinical trials have grown too heavy and need to be simplified without losing rigor. Her fixes are leaner protocols, less data collection, checking data in proportion to its risk, and more automation. She also says a hybrid staffing model and careful integration of acquired biotechs let a large company run trials quickly and reliably.

The central tension is between complexity and speed. Trials keep accumulating data points, checks and processes, often after a past inspection finding, while pricing and regulatory pressure demand faster delivery. Sheller says the updated international good clinical practice guideline (ICH E6 revision three) gives permission to do less, but only if teams define what is critical and document their choices. Technology helps, but people and partnerships come first.

Key insights

  1. Hybrid staffing makes outsourced staff work like Merck staff

    Merck uses roughly 60% own employees and 40% functional service provider (FSP) staff from contract research organizations. Both groups follow the same processes, email and equipment, so trial sites cannot tell them apart and get a direct contact at the sponsor.

  2. Acquisitions succeed when people and in-flight trials are protected

    After acquiring Peloton, Merck met staff face to face, set out clear retention plans and kept the running phase two team intact. Sheller says Peloton staff were still valuable two years later when Merck defended an inspection.

  3. Copy-pasted protocols have tripled the data burden

    Sheller cites a study showing trial data collection rose about 3.5 times in a decade. Merck now scores the burden a design places on patients and sites and compares it with competing programs, which pushes teams to cut endpoints that are not needed.

  4. Checking every data point by hand adds little

    A TransCelerate study found only 2-3% of critical data changed after 100% manual source data verification. The new ICH guideline treats risk proportionality as a principle, so Merck is moving toward central, programmatic monitoring.

  5. AI is most useful for trending minor deviations

    Merck wants to use natural language processing to spot trends in free-text protocol deviation reports, such as a missed ECG at week 13. That lets teams spend less effort on trivial deviations and more on serious ones, like a patient who was never consented.

Questions

What is a functional service provider model in clinical trials?

It is a hybrid staffing approach in which a company's own employees and staff from outside contract research organizations (CROs) work as one team under the same processes. Sheller says Merck runs about 60% in-house and 40% FSP, and trial sites cannot tell the two apart.

How did Merck avoid disrupting trials when it bought other biotech companies?

Sheller says Merck met staff face to face, set out clear retention plans and kept the in-flight trials running under the existing processes. It moved over only what was essential, such as the safety database, and it built a reusable integration playbook.

Why are clinical trials getting more complicated, and what can be done?

Sheller says protocols are often copied from earlier trials, so they pick up extra data points and eligibility rules that are not needed. Her fixes are starting from the research question, scoring how heavy a design is for patients and sites, and cutting extras like unneeded exploratory endpoints.

What is ICH good clinical practice revision three, and why does it matter?

It is the latest update to the international standard for conducting clinical research, which dates to 1996. Sheller says it makes risk proportionality a principle, meaning critical data gets the most rigorous checks and less important data gets lighter ones.

How does Merck want to use AI and automation in trials?

Sheller describes using AI to find trends in text reports of protocol deviations and to automate data cleaning and reconciliation across vendors. Merck is also building an automation hub linked to each function, with implementation of its new quality management model planned for 2026.

Facts

Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.

Merck invested nearly $18 billion in research and development in 2024 and conducts trials in over 60 countries at more than 21,000 sites.

“a company that invested nearly $18 billion in R &D in 2024 and conducts trials in over 60 countries at more than 21 ,000 trial sites”

0:00:06 · Ben Comer · R&D spending · 2024

Jennifer Sheller joined Merck in 2017 and initially worked on integrating acquired companies' R&D activities into Merck's operations.

“You joined Merck in 2017, Jen, and initially, I think, worked on integrating acquired companies' R &D activities into Merck's R &D operations.”

0:16:33 · Ben Comer · Career · 2017

Sheller says roughly half a million clinical trials are registered on ClinicalTrials.gov.

“I think there's a half a million clinical trials registered at clintrials.gov. And so it's just, it's exploded.”

0:04:41 · Jennifer Sheller · Trial volume

In the late 1990s, clinical research associates verified hospital records against handwritten triple-copy NCR paper forms, which later gave way to electronic data capture.

“when I first started in the late 90s, it was, you know, triple NCR paper. So we'd go out to the hospitals to make sure that the records in the hospital system matched what was handwritten on an NCR form.”

0:05:12 · Jennifer Sheller · Data capture · 1990s

Sheller spent about 13 years at Sanofi, then moved to the biotech Kyowa Kirin, and has now been at Merck for over eight years.

“I spent about 13 years at large pharma at Sanofi and went to a small biotech, Keowakirin, shortly thereafter, before coming back into large pharma here at Merck for over eight years.”

0:08:58 · Jennifer Sheller · Career

Andy Lee, a former Sanofi colleague of Sheller, moved Merck from a fully outsourced clinical operations model to an in-house one.

“So he came into Merck and really shifted the paradigm from outsourced, fully outsourced model to bringing everything in-house.”

0:10:06 · Jennifer Sheller · Operating model

Merck's clinical operations model uses about 60% of its own headcount and about 40% functional service provider staff.

“So he brought everything in-house and built an operating model where we have, you know, 60% headcount through our company and then 40% or so through functional service provider.”

0:10:35 · Jennifer Sheller · Staffing model

Sheller says unit-priced outsourcing contracts fit poorly because a safety signal can require extra monitoring, forcing change orders.

“if you have unitized pricing for a given study, X number of monitoring visits, X number of phone calls to a site, that's not the real world because you might have a safety signal where you need extra monitoring.”

0:15:14 · Jennifer Sheller · Outsourcing contracts

Merck received its first approval for a product from Peloton Therapeutics within two years of acquiring the company.

“I'll share the Peloton example that came forward with a product that we got our first approval within two years of acquiring Peloton.”

0:17:36 · Jennifer Sheller · Acquisition integration

Merck acquired a HIF2-alpha inhibitor from Peloton Therapeutics, with VHL-associated renal cell carcinoma as its first indication.

“we brought in the HIF2-alpha inhibitor from Peloton and renal cell carcinoma and VHL was our first indication.”

0:25:06 · Jennifer Sheller · Oncology drug

Sheller says the Acceleron acquisition, with a large phase three program, was probably Merck's most challenging integration.

“Accelerant had a large phase three program that was probably the most challenging integration.”

0:20:41 · Jennifer Sheller · Acquisition integration

During the Peloton integration, Sheller hired a summer intern to shadow the team and write the integration playbook that became Merck's operations standard.

“I actually hired one of my summer interns to extend her stay for a project to shadow us and build the playbook out.”

0:21:37 · Jennifer Sheller · Integration playbook

Sheller cites Merck's Prometheus acquisition as a return to immunology, an area Merck had not been in for a while.

“That was an area we haven't been in in a while with the Prometheus acquisition, for example.”

0:26:12 · Jennifer Sheller · Acquisitions

Sheller cites a study saying data collection in clinical trials has risen more than threefold over roughly the last decade.

“over the last decade or so, I think they quoted that we've increased data collection in trials more than threefold.”

0:29:00 · Jennifer Sheller · Data collection

The ICH good clinical practice guideline dates from 1996 and has now reached its third revision.

“this is, I think, from 1996, so revision three, and it's taken that long of time.”

0:34:29 · Jennifer Sheller · ICH GCP · 1996

Sheller says revision three of ICH good clinical practice makes risk proportionality a principle, applying more rigor to critical data and processes.

“Meaning, you don't treat all of your data the same. You focus on critical data, critical data and processes with a higher amount of rigor.”

0:35:05 · Jennifer Sheller · Risk proportionality

A TransCelerate study found only about 2-3% of critical data changed as a result of 100% source data verification.

“they showed only like two to 3% of critical data changed from all of that effort doing that cross check.”

0:35:39 · Jennifer Sheller · Source data verification

Sheller says Merck wants to use AI and natural language processing to trend non-important protocol deviations so teams can focus on serious ones.

“that's where AI can help me trend the non-important deviations for the oversight.”

0:38:30 · Jennifer Sheller · AI oversight

Some research sites told Merck they would not run a trial unless non-physician sub-investigators, such as nurse practitioners, were allowed under the R3 changes, and Merck changed its process.

“hey, look, we're not going to do this trial unless you do apply the R3 changes and having non-physician investigators or sub-investigators in the trial.”

0:44:11 · Jennifer Sheller · Site feedback

Sheller says about 5% to 8% of US cancer patients participate in a clinical trial.

“I think is 5 % to 8 % of cancer patients participate in a clinical trial, whereas many would be interested if they were asked.”

0:49:08 · Jennifer Sheller · Trial participation

Merck created the Let's Talk Trials education campaign for the whole clinical research industry rather than for Merck alone.

“Let's Talk Trials is something that we created for the industry, for clinical research as a whole. It's not specific to Merck.”

0:49:38 · Jennifer Sheller · Patient education

Sheller says Merck is resetting its operating model around risk-based quality management, with implementation planned for 2026.

“we're really focused, as I mentioned earlier, on resetting our operating model with risk-based quality management.”

0:52:52 · Jennifer Sheller · Quality management · 2026

Sheller says she has built an automation hub at Merck, linked to the organization's functions through matrix leads.

“So I build an automation hub and I'm pairing it up through the functions in our organization.”

0:53:28 · Jennifer Sheller · Automation

Chapters

  1. 0:01:44From public health to clinical operations

    Sheller explains how her mother's community nursing and an epidemiology degree led her into clinical research. This sets out her operations-first perspective.

    “I've always loved science. I've always had a passion for public health.”
  2. 0:05:12How trial operations have changed since the 1990s

    She traces the move from carbon-copy paper records to electronic data capture and notes that few comparable changes have followed. It frames why further modernization is overdue.

    “it was, you know, triple NCR paper”
  3. 0:10:35Why Merck runs a hybrid functional service provider model

    Sheller explains the roughly 60/40 split of Merck staff and contractors and why one team and one set of processes works better than study-by-study outsourcing.

    “one team, one set of processes”
  4. 0:17:36Integrating acquired biotechs without breaking studies

    Using Peloton and Acceleron as examples, she describes protecting people and ongoing trials, and building an integration playbook.

    “our model is focusing on preserving the science and the expertise”
  5. 0:27:25Stopping the copy-and-paste protocol habit

    She argues that lean protocol design and less data collection reduce burden on patients and sites. The whole data ecosystem needs simplifying, not only the protocol.

    “we have this bad habit of taking protocols and copying and pasting”
  6. 0:34:29ICH revision three and risk proportionality

    The updated good clinical practice guideline lets sponsors focus rigor on critical data. Sheller explains why 100% manual checking is losing support.

    “revision three is emphasizing risk proportionality as a principle, not an option”
  7. 0:38:30What modernizing trial operations really means

    She describes using AI to trend minor deviations, defining what is critical, and shifting from field checks to central monitoring.

    “that's where AI can help me trend the non-important deviations for the oversight”
  8. 0:49:08Widening participation with Let's Talk Trials

    Sheller explains the industry-wide education campaign and the low share of US cancer patients who join trials.

    “5 % to 8 % of cancer patients participate in a clinical trial”
  9. 0:52:522026 priorities: quality model and automation

    She sets out plans to reset Merck's risk-based quality model and automate at scale, alongside developing future leaders.

    “where we simplify with rigor and we automate at scale”

Transcript

0:00:06
Ben Comer

Welcome back to the business of biotech. I'm your host, Ben Comer, Chief Editor at Life Science Leader, and today I'm speaking with Jennifer Sheller, Senior Vice President and Head of Global Clinical Trials at Merck, a company that invested nearly $18 billion in R &D in 2024 and conducts trials in over 60 countries at more than 21 ,000 trial sites with more than 100 ,000 active patients supported, a pretty sizable clinical operation, I would say. I'm excited to chat with Jennifer about her career path leading up to her current role at Merck and the process for integrating clinical programs that Merck acquires.

0:00:48

And we'll also talk about the clinical trial modernization and democratization I want to get Jen's thoughts on that. We'll touch on Merck's functional service provider model, as well as what new tools and technologies Merck is using to improve clinical trial operations. Thank you so much for being here, Jen.

0:01:11
Jennifer Sheller

My pleasure. Thank you.

0:01:13
Ben Comer

You have more than 25 years of experience in clinical development and operations, beginning as a clinical research assistant and contract research as a clinical scientist at Wyeth before leading portfolio and disease area clinical operations at companies including Sanofi, Kiawa Curran, and now Merck, of course, both domestically and internationally. Jen, what attracted you first to clinical development as a field?

0:01:44
Jennifer Sheller

Yeah, I think like many of the professionals in clinical operations, especially, we sort of stumble upon clinical trial operations. I've always loved science. I've always had a passion for public health. My mom was a community nurse, and often in my childhood, she would take us around in different parts of the community running health fairs and clinics, and I was just very inspired by the impact that she made in her community. And for me, I always wanted to, you know, build a career in healthcare in some capacity.

0:02:15

And so I finished a degree in molecular biology, I realized I wasn't going to be a lab person. That just wasn't my thing. I had plenty of jobs in college to kind of tease that out. And then I went on straight to get a master's in public health epidemiology, balancing, you know, that public health impact with my love of science and data together. And then really, as I was graduating, I had a colleague who just said, hey, I'm working as a clinical research assistant at Covance in Nashville.

0:02:45

I was down at UAB in the South. And she said, you should check out this company in this field. It integrates a lot of what we have studied with clinical research design. And so that was my entree. I interviewed at Cobans, which is now Fort Triads, had a few different spinoffs from there. And I had my first job in Princeton, New Jersey as a clinical research assistant. And I was really attracted to the impact that you can make through clinical trials and also the need for good problem solvers and operational skills.

0:03:17

I'm the type of person who likes to get things done on my checklist and get things moving and feeling productive. So it was a great fit for me.

0:03:26
Ben Comer

Yeah, well, I would imagine with so many clinical trials going on all over the world, I know it's a big job to make all of the trains run on time, but you have to have that kind of personality. I would think that it's really focused on executing, on meeting very specific goals on a very specific timetable. That was not something that was daunting to you. You embrace that and enjoy that kind of work, I guess it sounds like.

0:03:53
Jennifer Sheller

Yeah. And I love the challenges because it's not textbook stuff, right? I mean, you have 60 pages of good clinical practice regulation, but then you have to apply that to the real world and not just one country or one hospital. So that was always very intriguing to solve for problems and help move forward clinical trials.

0:04:12
Ben Comer

Yeah. And that means working with people, lots of different kinds of people. lots of different kinds of health systems. That's right. That's right. Thinking, I guess, back to that early experience at Covance and all the way forward, you've worked at some other really large companies I've just named. What are the biggest or most impactful changes that have occurred in clinical development and operations since you got started back in the late 1990s?

0:04:41
Jennifer Sheller

I would say the volume of R &D that's really exploded over the years. You know, there was an uptick post-COVID, but it's progressively been increasing with the focus on science and R &D. I think there's a half a million clinical trials registered at clintrials.gov. And so it's just, it's exploded. And it was nice to see if there's a silver lining in the COVID pandemic that the public started to understand, you know, how new medicines and vaccines were made.

0:05:12

Operationally, I would say, you know, when I first started in the late 90s, it was, you know, triple NCR paper. So we'd go out to the hospitals to make sure that the records in the hospital system matched what was handwritten on an NCR form. And then as a clinical research associate, you'd be ripping off the forms. and however many you could bring back into house. And so as in the early years of my work there, that transformed into electronic data capture.

0:05:40

You know, so it's still, I would say, an area for modernization because today the staff at research sites have to enter it into a computer system, into our data collector, but it's really looking at the health record and seeing what needs to be pulled into the data collector. There are some pilots, you know, to automate some flow of the data. It's not so easy because, you know, looking across all these different countries and lack of standardization is an area ripe for modernization.

0:06:07

But paper to the electronic data capture was a huge one we all sort of reflect on. And we haven't had, to be honest, too many transformative changes like that in operations over the years. And now there's really a big push to be more modern technologies moving so quickly. So we're on the train and moving and changing and working on automation and things like that. And I would also say, too, precision medicine has been a tremendous evolution in drug development, and especially in oncology.

0:06:41

It's been game-changing with immunotherapies and really providing meaningful impact to the lives of cancer patients. When I ran trials many, many years ago in the traditional chemo radiotherapy models, I mean, the trials were short because the treatments didn't work. And now, you know, we're following patients for, you know, many, many years, which is really incredible.

0:07:03
Ben Comer

Yeah. And of course, now we're getting, you know, even better, not just, you know, novel cancer therapeutics, but even better, more targeted chemotherapy and better and more targeted radiopharmaceuticals. That's an area that I've been watching and is a really interesting one and especially for cancer. And I want to come back to the idea of modernization in just a minute. You know, I'm curious about, you know, you mentioned some of the technologies and the shifting from, you know, the previous shifting from paper to electronic data capture.

0:07:38

But, you know, there's still this sense that health care lags other industries. You know, there are still Excel files being used out there, still PDFs that don't exactly make it easy for data capture sometimes. And I wonder if there's an opportunity for drug development and health care more broadly to kind of leapfrog forward and maybe catch up with some of the industries that have moved forward. there's a whole other conversation there about, you know, the regulatory restraint and the need, you know, we're talking about human lives.

0:08:13

So everything has to be very carefully done. So it's not the same as other industries. But I am curious if there's an opportunity now, you know, to kind of catch up in some ways and get to a more modern, less complex system for conducting clinical trials. We'll come back to that, I promise, in a few minutes. But just thinking about your career trajectory and working at companies like Sanofi and Kiawa Curran, did those experiences help you think about strategy or models for clinical trial operations that you bring to your current job?

0:08:55

I'm sure that different companies do things a little bit

0:08:58
Jennifer Sheller

differently, right? They do. There's similarities, even in small biotech. Sometimes they're like mini pharmas, how they set up their functionalities. But I spent about 13 years at large pharma at Sanofi and went to a small biotech, Keowakirin, shortly thereafter, before coming back into large pharma here at Merck for over eight years. And, you know, what I really saw in operating models, there was a time in the industry where people, you know, pharma companies hired all their clinical operations staff.

0:09:28

And then there was this pivot where, you know, companies felt it would be best to outsource all the operations. And so there was sort of this massive shift to outsourcing. And it's really over time has sort of reverted back and it's a bit of a hybrid now. But what I saw in the large farm environment was, you know, outsourced, in-source works best because you need to be able to integrate directly into the teams making decisions and having a A company that sort of sits outside that's not part of the team creates different goals for teams, and it's not really a united front, and it becomes a little bit of a finger-pointing exercise, and there's maybe different goals and

0:10:06

missions that people are focused on. And the outsource models in the large companies is really challenging, but it is needed in small biotechs because they don't have the arms and legs that the big pharma has. So some of that functional outsourcing is really important. So what really attracted me in coming into Merck was through a leader who I worked with at Sanofi, Andy Lee. So he came into Merck and really shifted the paradigm from outsourced, fully outsourced model to bringing everything in-house.

0:10:35

So he brought everything in-house and built an operating model where we have, you know, 60% headcount through our company and then 40% or so through functional service provider. And so that enables really, and the functional service provider model, you know, in this environment, they follow all the same processes as the Merck team. So it's one team, one set of processes, one set of what do we feel is compliant? You know, what is the level of compliance?

0:11:03

We all have the same targets and goals and really infused integrating into one team. And as a clinical trial site, you wouldn't know if you were working with somebody who has a paycheck from Merck or if somebody has a paycheck for one of the CROs that's in the FSP model. And that's what sites really want. They want a direct contact to the sponsor. They want a direct contact to the person who's really leading the study so they can get quick answers and so that things aren't sort of hopping through different levels and takes a lot of time and churn to get, you know, the right source of information.

0:11:36

So for me, that was my biggest learning, you know, working across the different organizations and just understanding, you know, how do you bring the best of the talent together in a model that's going to work within the environment effectively?

0:11:52
Ben Comer

Yeah, let's talk a little bit more about the functional service provider model. It sounds like it's one that you like. I mean, you came to Merck and, you know, we're as a support, you know, a way to support that model. You like that model. How does that can you maybe just talk a little bit about how that is set up or how it works differently? You know, particularly in other countries where if you have a, you know, a local organization that you're working with and on a fully outsourced model, it's pretty easy to understand.

0:12:25

I mean, it's a kind of almost turnkey. You just hand a kind of everything over to the outsourced provider. Whereas with the functional service provider model, you have, as you say, you know, internal Merck employees collaborating very closely with these external groups. Is it is it difficult to set? I mean, you're you're working in, you know, 60 plus countries. Is it difficult to set up those functional service provider models in each of the areas where you're working?

0:12:54

Is there a kind of playbook now that you have to do it so that you can replicate it and do it easily?

0:13:00
Jennifer Sheller

Yeah. Yeah. Yeah. And there's definitely a certainly a common standard approach here. And it's really starts with partnership, you know, with the CROs and working together as partners. So the CRO understands the skill you're looking for and the oversight expectations and the standards expectations. And it's coming together regularly to get feedback on what's working and feedback from their staff because everyone brings diverse and, you know, good feedback and interesting ideas to the table. So, you know, you could these big CROs have a massive outreach globally.

0:13:34

Maybe not all CROs fit my 52 offices that we have, you know, in in the world. So you have to maybe have this CRO that manages two CROs that manage maybe, you know, this in Europe. Maybe you have different ones for Africa and Asia Pacific and the U.S. But having a core set of CROs that we work with, you know, for functional service providers has really been key. And then aligning on, like, what do we expect?

0:14:01

So we don't human resource manage the staff that come from the CROs. So you have to really develop expectations on what you expect their managers to do. And then have a forum where, you know, empowering in the country, for example, where the CRO management team works together with the Merck team so that they, you know, are partnering, giving feedback and making sure they're really working as one team. At this trial team level, it's really seamless. You know, like it's not they're sitting at a clinical trial team meeting and they wouldn't say, oh, well, that that CRM or country manager is from this CRO and this one is a Merck employee.

0:14:41

That's that's not how it works. They just it's seamless at the trial level because, again, we're all following the same standards, processes, Merck email, laptops, equipments, iPads for monitoring. So it's it's really integrating as one team and it works. And that's, again, that's really what attracted me to come to the Merck organization because of this operating model build and because of the challenges that I saw in the outsource model. You know, if you think of outsource model, typically it's you contract study by study.

0:15:14

But that's not how research works. So if you have unitized pricing for a given study, X number of monitoring visits, X number of phone calls to a site, that's not the real world because you might have a safety signal where you need extra monitoring. And then if you're in these unitized or outsourced contracts, then you have to worry about change orders versus flexing your staff across the trials because as one trial sort of dips, another one's going to pick up.

0:15:44

So you can have flexibility and agility to use your resources in a real world environment. And that's that's how trials work. You need to sort of shift folks around and it doesn't it doesn't work well when you have a large scale volume of trials and then you have to sort of unitize across each one.

0:16:01
Ben Comer

Yeah, right. And it makes sense what you said, you know, about having some core CDMO partners that, you know, once you've kind of set up this arrangement and then, you know, for example, want to go into an adjacent market or want, I guess, if it's a market that that particular CDMO is working in, then they already know, you know, the arrangement is already set up, the process is already set up, and it's easy to kind of seamlessly move into a new trial, into a new market, because you already have kind of the working orders established.

0:16:33

That's exactly right. You joined Merck in 2017, Jen, and initially, I think, worked on integrating acquired companies' R &D activities into Merck's R &D operations. And this is a topic I think that the business of biotech listeners will be interested in hearing from you on because of, you know, the amount of deal activity is, you know, one of the one of the positive things in the kind of broader funding environment that's happening right now. The IPO market is sluggish.

0:17:07

There are a few happening, but it's still fairly slow. But we are seeing deal activity kind of pick up a little bit. I wonder what you could say, Jen, about your approach and Merck's approach to integrating companies. Maybe you could use, for example, some of the companies that you worked with when you joined, Peloton Therapeutics, Velos Bio, Acceleron. What does that integration process look like?

0:17:36
Jennifer Sheller

Yeah, and maybe I'll start, you know, I'll share the Peloton example that came forward with a product that we got our first approval within two years of acquiring Peloton. And that's really, you know, our model is focusing on preserving the science and the expertise, hence the reason for acquiring the company. And, you know, in some of the integrations, Peloton was finishing their phase two and we started the phase three in our model. So that was a little bit easier, although they had an ongoing registrational phase two where we had to really keep the team intact.

0:18:11

So it's, you know, when biotechs get the word of acquisition, you know, there's probably mixed emotions depending on the levels. But most people are worried about their jobs, right? They're supporting their families and it sets a bit of panic. So the first thing, you know, as a leader and approaching an integration, and I was like the operational lead for R &D, was really getting out there face to face. It's invaluable straight away. And just making sure that people understood the ethos of our company and how we're a people first company and high bar of ethics.

0:18:46

And, you know, we will make sure that people are cared for in this environment. And that's what we did. And we made things very clear on retention. And we wanted the talent to stay. And we made a concerted effort to interview everybody who wanted, you know, to stay with the company and where there could be a potential fit. And that's not always the case because the profiles perhaps at biotechs largely aren't always interested in coming into large pharma.

0:19:10

But the face-to-face piece and the connection is key. And then really understand what you're getting, making sure you have a robust sort of due diligence debrief with your broader Merck team who's going to have to help shepherd, you know, the acquired company in through all of the Merck systems and processes. But what's really important is doing an assessment. And this is, I think, where my background comes into play because I've done insourced and outsourced.

0:19:37

I'm not stuck on one company way of working, but looking at, you know, how trials are running and deciding, like, what's really needed to move into the Merck process and system? Probably things like the safety database over time. What's okay to keep as is because it is GCP compliant. It might not be the way that, you know, Merck would do it in their model. But what can we keep running and keep that pivotal, you know, registrational phase two going?

0:20:04

That was a rare disease indication that got approval. So it's really having sort of that pragmatic approach and also approaching, you know, the biotech staff that, you know, we're going to learn from them. It's not just us coming in and taking over and acquiring, but what can we learn from you and approaching it in a collaboration way? And then you've got to make sure that each function that supports clinical trials has their own sort of playbook of things that they need to go through to make sure that they have covered and some of the fundamentals and processes for clinical trials so that we're mitigating any risk if there's any gaps.

0:20:41

You know, a lot of times it can involve re-looking at the CRO contract. Was it too skinny, too light? Do we need to make sure that there's enough monitoring built in here and so on and so forth? And then having a kickoff with the outsource parties as well. So it's all about, you know, connectivity, the people component, but then really bringing in, you know, the process without disrupting, especially for in-flight. Accelerant had a large phase three program that was probably the most challenging integration.

0:21:10

So we really had to preserve and make sure that those studies were supported and running without trying to mercify things, as we say, and shifting ways of working. There's some things inherently that you just have to move over. But by and large, in operations where you can sustain and maybe enhance a little bit of the standards was really the approach we took. And then building a governance so you can make sure that we have the right controls and oversight.

0:21:37

And, you know, when I came into the Peloton integration, it was we didn't have a playbook. We didn't have like a standard way of doing it. So we built it along the way. And I actually hired one of my summer interns to extend her stay for a project to shadow us and build the playbook out. We had some consultants come in and it was creating more chaos than no offense to consultants, but it was creating a lot more chaos than help.

0:22:03

And so we had her sort of shadow us and built this beautiful playbook. And that's became the foundation and standard for how we we conduct our integrations from an operations standpoint moving forward.

0:22:16
Ben Comer

Oh, that's that's really interesting. And so you have a playbook, but it sounds like you're also approaching each company, you know, in a unique way, looking at them as a unique organization, what they need, maybe what they don't need. And so there is a little bit of give and take. It's not like, you know, is the complete standardization, no matter what phase you're in or what, you know, therapy you're developing. There's, you know, you're looking at an individual company and making some decisions that may not be the same for each company in terms of how you do that integration.

0:22:48

Is that fair to say?

0:22:49
Jennifer Sheller

That's fair. And I think, you know, the respect for people part is really key because I've heard some horror stories of of other integrations where companies just came in and said everyone's gone in three months. And, you know, for Peloton, they got the messaging very early that they had a long transition plan, you know, and in between we would support them to look at opportunities if they were interested in staying in the long term. So it's really kind of reducing that anxiety and taking the, you know, taking care of people is really fundamental to making it successful because you need people to still be engaged.

0:23:24

You know, there's trials that are active and running. And, you know, as our company, we weren't ready to just jump in and take over. We had no idea of ways of working, processes. And it's not all cleanly outsourced to a CRO in many cases. A lot of times the biotechs will have different functions running certain sections on their own process. And it's a lot of mixed ways of working that you need time to understand and get your team on the ground.

0:23:48

And I would say, you know, for Peloton, defending an inspection two years after integration, it was really important that we still had Peloton staff with us to help explain some of the history. And that was that was invaluable. And that's really only possible because we approach them, you know, cross-functionally as one team to to really come in and value their experience and and delivery.

0:24:11
Ben Comer

Right. I mean, we've seen some and I think it's less I see it less commonly now. But larger pharmaceutical companies who at times I've seen in the past acquire a company and say, we're going to let this company work completely independently. You know, we're going to be we're going to be here for support, but we're going to be sort of hands off. And I think you kind of alluded to the challenge with that type of arrangement.

0:24:36

I guess I'm thinking, you know, of Bayer and a number of companies that they acquired kind of in the cell therapy area. But what, you know, what I guess is the challenge with doing it, running it that way, letting a company be wholly independent? What, you know, what what difficulties, I guess, are presented by by that arrangement versus a kind of custom integration that you're describing?

0:25:06
Jennifer Sheller

Yeah, I guess there's a lot of different models of how you can approach it. And I think, you know, a standalone model can preserve a therapeutic area. maybe that the company doesn't have, you know, it would take a tremendous amount of effort to build. And I think having the right governance model in place, that can certainly be successful too. But where you're integrated, like for oncology, we have a lot of experience. You know, we brought in the HIF2-alpha inhibitor from Peloton and renal cell carcinoma and VHL was our first indication.

0:25:37

We had a very well-established oncology therapeutic area to integrate into. So, So, you know, it just probably depends on the breadth of the company's experience because it'll take a lot to upskill in a new therapeutic area.

0:25:51
Ben Comer

Is Merck currently, you know, in terms of acquisitions, I'm not going to ask you, you know, who Merck is going to acquire next. But are you focused kind of on those seven key therapeutic areas plus vaccines or does, you know, Merck think about acquiring companies beyond, you know, areas where you're currently focused?

0:26:12
Jennifer Sheller

Yeah, I don't know that I could speak well to that. I mean, our focus is following the science and bringing the best value to the patients. We've had a lot of diversity in our acquisitions. You can look at immunology. That was an area we haven't been in in a while with the Prometheus acquisition, for example. So we have quite a diverse portfolio as it stands today and growing.

0:26:38
Ben Comer

Clinical trials, you alluded to this earlier, have gotten more complex over time, driven by new drug modalities, new regulatory designations and pathways, new scientific discoveries, among other things. regardless of company size, developers are looking for ways to simplify and modernize clinical development to be as efficient as possible, especially in a time when funding is not always easy to obtain for smaller and mid-sized biotechs in particular. But they don't want to miss out on potential value that a new development candidate represents.

0:27:18

What are your thoughts on how protocols can be simplified?

0:27:25
Jennifer Sheller

Yeah, and this is, I would say, really a huge opportunity in the industry because we have this bad habit of taking protocols and copying and pasting, you know, similar indications to the other and bringing forward maybe some extensive data collection points or inclusion-exclusion criteria that aren't necessarily needed. So we are focused on protocol lean design as a key initiative or objective for our development organization. And it really needs to you need to start with the end in mind, you know, that we have to stop the copy paste.

0:27:57

And, you know, what particular research question are you answering? What do you need to answer that question from an endpoint standpoint? We have a tool where you can plug in the schedule of activities that measures site burden and patient burden and looks at it like in a competitive landscape to say, you know, if you have a phase three and this indication, what it looks like from a burden score compared to, you know, other programs and really having discipline to take things out.

0:28:29

And the other thing I think we really need to think about is just, you know, as you think about the ICH, good clinical practice framework, it's fit for purpose, focusing on what matters and being very cautious to add any extra burden into the system with exploratory endpoints, for example. And maybe even some of the secondary, do you need to assess it in all patients in a phase three? Or could you do a sub-study? Do you need your visit frequency every two months?

0:29:00

Or could you have some flexibility with your visit windows? Could there be visits that are done remotely and built into your schedule events? So easing the burden for patients. But protocols are becoming more and more complex. And this is really an area that we all have to double down on. There was a really interesting, tough study recently that looked at data collection. And, you know, over the last decade or so, I think they quoted that we've increased data collection in trials more than threefold.

0:29:30

I think it was like 3.5 increase in data collection. So it's not just, you know, specifically the processes and visits, procedures that you're putting into your designs, but also the volume of data that you're asking to correlate for that. So we have to have good discipline and rigor. And then, you know, when you think about protocol simplification, the whole ecosystem needs to be simplified. So as you're, you know, leaning your protocols, you need to start to think about leaning your data collection so it's fit for purpose.

0:30:02

And then how you clean the data. You know, we're looking very deeply at how our teams are querying the data, which adds work to our research sites, right? And so do we need to query all data the same? You know, can you tier your data? So it's more risk proportionate. So really looking at it, I would say the full ecosystem downstream of the protocol development and simplifying. We've just become incredibly complex over time and trying to answer a lot of research questions in one design and where we can focus on what's most important will really help everyone at the end.

0:30:40
Ben Comer

And that's really interesting. It kind of reminds me of, I think, you know, a period, maybe five or 10 years ago where there was a lot of excitement about new types of data that could be captured. And there was a feeling almost that, you know, the more data, the merrier, like, let's just, you know, like capture as much data as we possibly can. And then on the back end, we'll figure out, you know, where where the value is.

0:31:05

But, you know, what you're saying is that that, you know, complicates trials. It makes them perhaps last longer, cost more, and that there needs to be, you know, a kind of trimming, you know, bringing this, you know, focusing it more to answer a specific question that you're trying to ask rather than, you know, just simply capturing as much data as you possibly can.

0:31:28
Jennifer Sheller

That's right. And think about the burden. You can think of, like, the ECOA assessments, the outcome assessments or the pros, they would call them, patient-reported outcomes. So, you know, trials have added lots of those into the system that collects a lot of data. And then that requires quality control and cleaning and reconciliation. So that's for you have to add that work into your team. Then you have to add that work into the clinical trial sites.

0:31:54

And what I've noticed just over the years is while we've thrown out a lot more data, We haven't developed cleaning mechanisms that apply the technology rigor of automation to do this in a very efficient manner. So you see a lot of sort of old skills being applied to clean massive amounts of data. You know, you still see sometimes Excel for diary information that's collected in, you know, thousands of patients. And so this is where we're really working to support our teams and bring more of the technology skills.

0:32:28

but we need it from the vendors too. There's a lot of vendors in the clinical trial environment. You have lab vendors, you have the ECOA vendors, you have the IRT vendors. I mean, you probably have seven or eight different vendors in any given study. And that's a lot of data collected across them. And what I'd like to see more holistically is just mechanisms to automate more of the reconciliation versus putting the burden on the sponsor teams to try to figure out and build tools And one area that our industry is really trying to figure out these days is how do we leverage audit trail data in systems to give us, and we have to start to do this because it's

0:33:10

become part of the good clinical practice guidelines, but, you know, how can we do this at scale with efficiency to give us quality control signals in our trial oversight? So all that new data has come in. I would say it's been a bit of old fashioned cleaning and and reconciliation. That's really an opportunity to not only trim, but then, you know, identify more efficient ways to to do quality control of this massive volume of data.

0:33:37
Ben Comer

You mentioned the ICH, the International Council for Harmonization, I believe. Would you mind just mentioning how, you know, whether Merck works directly with that group or how you use the various tools and guidance that they provide?

0:33:55
Jennifer Sheller

Yeah, and so that really, the ICH Good Clinical Practice Framework is the international standard for conducting research. So, I mean, we're all following ICH Good Clinical Practice. That's the foundation. And that gives the common core of how research can be done globally with a common set of standards. The U.S. is an adopter. Many of the large countries are adopters. And it's the framework you'll see in probably any global company. So they haven't updated the good clinical practice guidelines quite very often for a long period of time.

0:34:29

I think it was like 10 years before the section around clinical trial oversight was updated. And then they updated again in a couple years. So we had a recent update this year, and that's revision three. And, you know, this is, I think, from 1996, so revision three, and it's taken that long of time. But revision three is really, I would say, a tailwind in the clinical trial operational delivery because revision three is emphasizing risk proportionality as a principle, not an option, but as a principle of how research is conducted.

0:35:05

Meaning, you don't treat all of your data the same. You focus on critical data, critical data and processes with a higher amount of rigor. You take more risk-based approaches, you know, in your data cleaning and quality control. And our industry has really struggled with that over the years. You still see some organizations doing 100 % manual cross-checks, what we call a source data verification. So sending people in the field to do 100 % checks of what's in your collector versus what's in an electronic health record.

0:35:39

And we found even 10 years ago plus, there was a paper that, you know, really kind of dispelled the myth of the value of doing that crossjack with Transcelerate, which is a consortium of pharma, you know, working to advance our industry and bring forward best practices. And they had a really interesting publication and study where they showed only like two to 3% of critical data changed from all of that effort doing that cross check. But yet you still see organizations, many organizations are shifting away from that.

0:36:11

And some are even thinking, do I need to do that check at all? Can we just determine the outliers and anomalies and centralized methods? So we're sort of playing us. We're playing around right now. We don't do 100%. We're looking to see how we can do more central monitoring to sort of support quality control measures. But, yeah, it's really lots of opportunity. It's been a slow evolution. But I really think today with the pressures, the pricing pressures in our pharma landscape, but also, you know, the regulatory changes and pressures need to go fast, it's not optional.

0:36:45

And technology is certainly providing a lot of opportunity where we can take this and run and do things differently.

0:36:51
Ben Comer

I think this is a great segue to the idea of modernizing clinical development. It's something that I've heard FDA Commissioner Mackery talk about recently, the importance of modernizing the clinical enterprise. as other biotech and pharma leaders have mentioned it. And I'm curious what modernization means to you in this context. And maybe we've already been talking about modernization, but what does it mean to modernize clinical trials? Yeah, I would say from an operational standpoint,

0:37:25
Jennifer Sheller

not a design standpoint, because there's lots of opportunity. I'm sure that's, you know, in the strategic thinking of the FDA. But, you know, when I think about modernizing clinical trial operations, I think about simplifying with rigor based on that R3 update, you know, with really focusing on risk proportionality and making sure that processes aren't overly heavy. So we've sort of, what happens I think over time is, you know, you develop processes, you get an inspection, oh, there's a finding, and then you apply, you know, a lot of change and extra checks in place.

0:38:01

And, you know, coming back, is this worth it? Is it working? Is it adding value. Like really, for me right now in our environment, we have to challenge our ways of working. And, you know, I'll give you one example. We have in clinical trials, you have to collect deviations from the protocol. So if a clinical trial site isn't compliant with your protocol, you have to log all those deviations. Some are not important. Could be you're a day out of window for your visit, you're late on something, and some could be incredibly important.

0:38:30

Like there a patient wasn't consented for a trial. That applies a different level of focus. And, you know, in some of these processes, we apply the same amount of rigor to those non-important protocol deviations as we do to the important ones. So for me, that's a dial down. You know, that's where AI can help me trend the non-important deviations for the oversight. So when we see trends, you know, using natural language processing, because there's a lot of qualitative text and how these things are reported.

0:38:58

There's categories too, but to get into the meat, you have to dig in a bit. I think that's where teams are struggled. But here, this is where AI can help, you know, directing our teams to trend better and to say, hey, this is a trend we're seeing and ECG's missed at week 13 and sort of understanding the patient journey and the flow and maybe digging in there versus going, you know, patient by patient and in the review and providing maybe a bit too much resource and effort.

0:39:27

So simplifying with rigor, focusing on what matters most, we are really focused on redefining our risk-based quality management operating model, which is really looking at how do we define what is critical first? Because, you know, a lot of times you can see teams identify 50 different things that they think that are critical, but that's not providing, you know, sort of that differentiation focus. And you need experience to help teams with that, to say, this is your primary endpoint, he's secondary, this is most critical, you know, and really try to help our teams narrow that down and couple that with, you know, highly robust oversight, coupling more of that central monitoring type of activity.

0:40:09

And that would be programmatically cross-checking data versus sending that person in the field, you know, just relying on that type of check. And then thinking about like your other tiers of data and what types of quality checks you want to put in place. It could be, you know, maybe you apply an edit check on a data that's not critical and you issue questions to the site if it's out of a range and then you leave it when the site responds versus, you know, continuing to sort of perseverate on it and applying different decisions that apply true risk-based methodologies into ways of working.

0:40:43

So that's how I view modernization. You know, it's really applying more fit-for-purpose ways of working. You have to document it. You know, you have to be very clear on your decisions and documenting. But there's just been a lot of, I would say, old-fashioned ways of working and traditional ways of working. I think an over-reliance on manual checks that happen in the field and how that's all documented versus modernizing through, you know, programmatic reconciliation, automation of checks, all that external data that I mentioned that was coming in and making sure teams have a dashboard where they can see this site is missing.

0:41:25

You know, they didn't do this procedure at this visit and they're red. You know, they need a follow-up. You have to send that field person out to retrain and get them back into compliance. So that to me is really where we can be more effective, efficient, and leveraging technology to how it can best support our teams. I have one funny story. We bring a lot of interns in every summer and really trying to infuse blending sort of tech skills and clinical scientist skills.

0:41:55

And one of our interns shared with me, I said, so how's it working? Do you have any ideas like on where we can automate more, where you're seeing a lot of heavy Excel tracker, you know, movement and email updates and things like that? And she said, Jen, she's like, it's not even using just Excel. She's like, they're not, I see people using Excel as a Word document, like typing a lot of text into Excel and not applying formulas.

0:42:19

So there's a lot of opportunity to really help and make things, you know, more automated and efficient. And it's, It's people just have to have an open mind to to learn from others and see how things can be done differently.

0:42:33
Ben Comer

And so at Merck, when you're wanting to maybe introduce new tools to improve, you know, this process, dial something back, as you mentioned, is that a conversation that you're having through the functional service provider group of folks? You're talking to the site as well as internally with people at Merck and kind of getting agreement and at least, you know, informing everyone, you know, how something is going to change going forward. Is that right?

0:43:03
Jennifer Sheller

Yeah. Yeah, and we have, exactly, we have a process owner network. So like owners of specific, you know, we have all these processes to follow in clinical development and how you run your study is governed by your processes, which are in line with those ICH guidelines that I mentioned. So for me, it starts with the process owner, make sure they have the right training to do lean design and efficiencies and also couple them with technology experts so they can look at the process from first a simplification manner, but then where can technology help perform some of these areas of the process?

0:43:39

The example I mentioned with, you know, the deviations and using AI to do trending and, you know, it's sort of coupling and mirroring those types of skills, but then we don't make decisions in a vacuum. So we engage our teams, those that are working at the clinical trial level, and that could be the FSP resources through the CRO, or it could be our own headcount staff. And if it's a process that involves or impacts our clinical trial sites, we do survey our sites every year to say what's working well, where do we need to improve?

0:44:11

But we also have a network of sites that we tap into and sit down and walk them through what we're thinking. What do you think? Does this make sense? And we've had some sites who came forward and said, hey, look, we're not going to do this trial unless you do apply the R3 changes and having non-physician investigators or sub-investigators in the trial. We can't do this study unless we can use our nurse practitioners. So we brought it back to our development forum.

0:44:38

It's beyond operations. And we changed our process, you know, where we now have built into the protocol where it's appropriate to have the non-physician sub-investigators. So it can go both ways. You know, it can be driven by us. And as we learn through our peers, we're part of a lot of industry consortiums, but it can also bubble up from research sites around the globe to tell us, hey, this isn't working. We need to change, and we're open, and we listen.

0:45:05

And having a seat at the table from our clinical trial sites is so important that we don't turn into ivory tower

0:45:12
Ben Comer

decision makers. Is it possible for sponsor companies that maybe don't have this functional service provider model are working in more of a fully outsourced model to communicate with their CDMO partners and have that kind of information exchange and even, you know, make some changes? It may be more difficult. I don't know. But are there is there any advice, I guess, that you would have for perhaps smaller biotech companies who are working on more of a fully outsourced model, you know, how to think about and implement some of those things?

0:45:47
Jennifer Sheller

I mean, you know, from my experience in the biotech and working through all these integrations, my advice is treat your CRO like a partner. Because if it becomes a very tactical relationship and fear-based and finger-pointing, you won't get anywhere. I had one, you know, environment where I really had to turn around some of the relationships and the team dynamics to make sure that we were listening to the CRO. They had, you know, they had very valid feedback and points and behaviors that we needed to change, you know, on the sponsor side.

0:46:18

So I would just really encourage you approaching it like a partner. And every sponsor, biotech or big pharma, should be sitting down with sites regularly. I think biotechs do a nice job at getting out there because, you know, at all levels, they're really vested in partnering with sites and getting their feedback and having the CRO sort of around the table as one team, even if it's not an FSP model. I think the behaviors and the way that we work together in a partnership way just goes a tremendous way.

0:46:49

Every year we have a forum where we celebrate, we bring in all of our supplier leaders, not just FSP, but the labs, all the key vendor leaders across the ecosystem that we couldn't frankly do this work without. And we come together and we talk about like, you know, the vision and the strategy, our portfolio. And then we also celebrate, you know, how where things worked well. And, you know, we have forums where they're bringing forward. They've got a bigger line of sight across the industry, too.

0:47:19

Like, where are they seeing ways that we can improve? So for biotechs, it's, you know, it's just be open to feedback. And operations makes a difference. You know, it's not just the science, the beauty of the science, but it's being able to execute in a feasible manner really makes a difference. And I would also just add, when we talked about simplifying protocols, one key area is bring the sites in early. Don't just hand them a final protocol.

0:47:46

Like walk the protocol with your sites. Maybe walk it with your lab vendor to make sure all these, you know, shipments are feasible across the different specialty labs and what the turnaround time is going to be and how that impacts, you know, a patient who's waiting to know if they're eligible for a cancer therapy. So, you know, taking the proactive steps up front just goes a tremendous, tremendous way.

0:48:09
Ben Comer

And listen to their feedback, too, right? And, you know, what they have to say based on, you know, their experiences working specifically in those areas. Yeah. Merck recently launched a campaign called Let's Talk Clinical Trials, which I think aims to expand the number of people who participate in clinical research. Is clinical trial diversity an area that you are focused on in operations?

0:48:37
Jennifer Sheller

Absolutely. And it's always been. It's always been a core of how we work. And you have inherent diversity by our country footprint. But we also have special focus on our U.S. population to make sure that we're not approaching all patients in the same way. You know, educational methods need to differ. And also engaging in the community has been a big focus for us. You know, typically in trials, you focus on the site, you know, but we have to go broader than that.

0:49:08

And when you look at the U.S. as an example, I think is 5 % to 8 % of cancer patients participate in a clinical trial, whereas many would be interested if they were asked. And, you know, I don't know about you, but, you know, I know friends who've had cancer and I'm trying to explain to them where clinical trials could be. It's very difficult for a layperson to understand how to even access a trial. It's not all the healthcare providers are going to be giving recommendations for particular trials for patients.

0:49:38

So education is key. Let's Talk Trials is something that we created for the industry, for clinical research as a whole. It's not specific to Merck. And it's providing education on what are trials, perhaps dispelling myths on what people think trials are, hearing from patients, hearing from community members, understanding all the rigor and ethics reviews that goes into approving a clinical trial. And it's really just putting it out there, you know, in basic terms so people can understand that it is a care option.

0:50:14

and here's how you find, you know, ways. ClintTrials.gov is a bit of a nightmare to sort through. We have a beautiful website, a clinical trial finder. I know other companies do as well, but the more we can educate as a potential care option, especially when, you know, patients are suffering and they're out of options, you know, to ensure that this is better understood. I think during the COVID era, you know, the public really started to understand, but that fizzled out a bit.

0:50:40

So we have to really have more intentionality in our communication about, you know, what clinical trials are. I love Let's Talk Trials, and it's something that many of us who've been in the industry for a while have been really yearning to see. And I'm really proud of our company for putting the effort here.

0:50:57
Ben Comer

Yeah, well, I mean, I would think part of it, too, has to do with engaging and educating community providers. And I wonder if, you know, this ever, you know, thinking about community providers and making sure that, you know, they're even notifying their patients about, you know, that the provider themselves knows about the trial and that they're identifying their own patients to potentially participate. I mean, I wonder if that ever, you know, calls to mind some of those early experiences you had with your mother going to, you know, a community health center.

0:51:32

I mean, is that something that you're thinking about as well?

0:51:35
Jennifer Sheller

Yeah. And, you know, I would love my dream would be like when you get your electronic health record as a printout, you know, from your visit, you get your visit summary. Wouldn't it be great if it sort of automatically populated active clinical trials in your vicinity for maybe a disease that you're suffering from? At least to kind of allow the patient to have a choice and maybe a barcode to get to Let's Talk trials so they could say, like, what is a trial?

0:52:01

You know, what does this involve? And really to make it automatic through the health care system, to me, would be the dream. You know, continuing to educate, educating communities. It's a strategy that we've deployed through many different partners. This is one method of doing it. And we've also had intentional boots on the ground to do it as well. But we all need to put our efforts in here to continue to educate and allow patients and their caregivers to make choices.

0:52:31
Ben Comer

Right, right. Well, we are coming up on the end of our time here. But before I let you go, Jenna, I wanted to ask about next year, looking forward to 2026. We're coming up on the end of the year here. What are some of your professional priorities at Merck? And then what are some of your personal priorities?

0:52:52
Jennifer Sheller

So, you know, professionally, it's delivering this diverse and vast portfolio with high quality. And we're really focused, as I mentioned earlier, on resetting our operating model with risk-based quality management. So balancing more of the central monitoring with the site, that's going to be a really important focus for us. It is right now and for implementation in 2026. So we're using our roles most effectively on the most important data. So that's really key. I would say creating an environment where we simplify with rigor and we automate at scale.

0:53:28

So I build an automation hub and I'm pairing it up through the functions in our organization. They all sort of have matrix leads into the hub and building this now into process officially. So it's, you know, we've had a good time with experimentation on things like co-pilot and tools, and there's different adoption of great tools like Power Automate and BI and things like that. So it's really simplifying with rigor, automating at scale, and making our work more efficient and productive so we can do more because we know we need to continue to fuel our R &D engine.

0:54:01

And, you know, from a personal standpoint and, you know, professional as well is really taking care of my leadership team, making sure that they have the right skills to help their teams optimize. I need growth mindset and people to get behind why we need to evolve and modernize. So it's making sure I'm bringing my leaders along and supporting them and then building the future leaders. You know, it's really building the future leaders of clinical trials. It's, to me, pairing up some of these heavy tech skills with the clinical skills so that they can come together and sort of have a best of skill set for what this environment needs.

0:54:38

And, you know, always as a leader, I think it's important to take care of yourself physically and take care of your health so you show up well for your team. So that's a commitment to me as well as making sure I'm upskilling my digital acumen in this environment too.

0:54:55
Ben Comer

Right. Excellent. Well, thank you so much for being here, Jen. I really appreciate it.

0:55:00
Jennifer Sheller

Thank you. Thanks, Ben.

0:55:01
Ben Comer

We've been speaking with Jennifer Sheller, Senior Vice President and Head of Global Clinical Trials at Merck. I'm Ben Comer, and you've just listened to The Business of Biotech. Find us and subscribe anywhere you listen to podcasts, and be sure to check out new weekly video casts of these conversations every Monday under the Business of Biotech tab at lifescienceleader.com. We'll see you next week, and thanks, as always, for listening. We'll be right back.